ANIK
Anika Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+18/100
Last price
19.12
▼ 0.61 (3.09%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
19.73
Day high
19.80
Day low
19.05
Volume
64.73K
Market cap
$255.88M
P/E (TTM)
—
52W range
8.67 – 22.88
Trailing performance
Returnvs SPY
1W
-4.16%
-6.1%
1M
-8.12%
-9.3%
3M
+17.01%
+12.5%
6M
+28.15%
+10.0%
YTD
+98.96%
+84.7%
1Y
+110.80%
+94.4%
3Y
+2.63%
-79.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
16 more panels on ANIK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
856.91K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 4, 26 | FISCHETTI GARY P. Director |
BUY | 2.00K | $41.06K | Direct |
| Jun 18, 26 | CONLEY SHERYL L Director |
STOCK | 10.40K | $0 | Direct |
| Jun 18, 26 | CAPPER JOSEPH H Director |
STOCK | 10.40K | $0 | Direct |
| Jun 18, 26 | HENNEMAN JOHN BELL III Director |
STOCK | 10.40K | $0 | Direct |
| Jun 18, 26 | RICHARD STEPHEN Director |
STOCK | 10.40K | $0 | Direct |
| Jun 18, 26 | FISCHETTI GARY P. Director |
STOCK | 10.40K | $0 | Direct |
| Jun 3, 26 | GRIFFIN STEPHEN D Chief Executive Officer |
— | 12.84K | — | Direct |
| May 1, 26 | HENNEMAN JOHN BELL III Director |
BUY | 5.00K | $73.32K | Direct |
| Apr 30, 26 | GRIFFIN STEPHEN D Chief Executive Officer |
BUY | 12.20K | $149.88K | Direct |
| Mar 13, 26 | BLANCHARD CHERYL R Director |
STOCK | 24.52K | $0 | Direct |
| Mar 13, 26 | MCLEOD IAN W Officer and Treasurer |
STOCK | 1.16K | $0 | Direct |
| Mar 13, 26 | COLLERAN DAVID B J.D. General Counsel |
STOCK | 4.69K | $0 | Direct |
| Mar 13, 26 | GRIFFIN STEPHEN D Chief Executive Officer |
STOCK | 6.41K | $0 | Direct |
| Mar 13, 26 | COLLERAN DAVID B J.D. General Counsel |
— | 15.84K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLANCHARD CHERYL R |
Director | 270.53K | Stock Award(Grant) |
CAPPER JOSEPH H |
Director | 30.80K | Stock Award(Grant) |
COLLERAN DAVID B J.D. |
General Counsel | 67.57K | Stock Award(Grant) |
CONLEY SHERYL L |
Director | 52.97K | Stock Award(Grant) |
FISCHETTI GARY P. |
Director | 54.02K | Purchase |
GRIFFIN STEPHEN D |
Chief Executive Officer | 45.97K | Conversion of Exercise of derivative security |
HENNEMAN JOHN BELL III |
Director | 65.27K | Stock Award(Grant) |
LARSEN GLENN R |
Director | 50.26K | Stock Award(Grant) |
RICHARD STEPHEN |
Director | 58.27K | Stock Award(Grant) |
VOGT SUSAN L N |
Director | 50.21K | Stock Award(Grant) |
Fundamentals
Market cap$255.88M
Enterprise value$242.72M
Revenue (TTM)$120.65M
Gross profit$75.00M
EBITDA$3.04M
Net income$-3.12M
EPS (TTM)$-0.23
Free cash flow$3.06M
Total cash$38.41M
Total debt$25.25M
Book value / share$10.26
Shares outstanding13.38M
Float11.29M
Short % of float3.74%
Dividend yield0.00%
Beta (5Y)0.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E20.13
PEG ratio2.08
Price / sales—
Price / book1.86
EV / revenue2.01
EV / EBITDA79.84
Gross margin62.17%
Operating margin11.43%
Profit margin-3.14%
Return on equity-2.19%
Return on assets-0.87%
Debt / equity18.39
Current ratio4.48
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $112.82M | $119.91M | $120.79M | $113.83M | -5.9% |
| Operating revenue | $112.82M | $119.91M | $120.79M | $113.83M | -5.9% |
| Cost of revenue | $49.01M | $43.91M | $38.26M | $40.61M | +11.6% |
| Gross profit | $63.81M | $76.00M | $82.53M | $73.22M | -16.0% |
| Research & development | $25.77M | $25.54M | $21.76M | $18.32M | +0.9% |
| Selling, general & admin | $49.09M | $55.55M | $59.92M | $51.23M | -11.6% |
| Total operating expense | $74.86M | $81.10M | $81.69M | $69.55M | -7.7% |
| Operating income | -$11.05M | -$5.10M | $844.00K | $3.67M | -116.6% |
| Net interest income | $1.74M | $2.34M | $2.31M | $654.00K | -25.4% |
| Pre-tax income | -$9.31M | -$2.76M | $3.16M | $4.32M | -236.7% |
| Tax provision | $672.00K | $6.06M | $6.59M | $2.12M | -88.9% |
| Net income | -$10.88M | -$56.38M | -$82.67M | -$14.86M | +80.7% |
| Net income to common | -$10.88M | -$56.38M | -$82.67M | -$14.86M | +80.7% |
| Basic EPS | -0.76 | -3.83 | -5.64 | -1.02 | +80.2% |
| Diluted EPS | -0.76 | -3.83 | -5.64 | -1.02 | +80.2% |
| EBIT | -$11.05M | -$5.10M | $844.00K | $3.67M | -116.6% |
| EBITDA | -$5.32M | $3.02M | $15.06M | $18.16M | -276.2% |
| Basic shares | 14.34M | 14.72M | 14.66M | 14.56M | -2.6% |
| Diluted shares | 14.34M | 14.72M | 14.66M | 14.56M | -2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $57.48M | $55.63M | $68.74M | $86.33M | +3.3% |
| Cash & short-term investments | $57.48M | $55.63M | $68.74M | $86.33M | +3.3% |
| Accounts receivable | $23.69M | $23.59M | $26.36M | $34.63M | +0.4% |
| Inventory | $18.79M | $23.81M | $24.43M | $39.77M | -21.1% |
| Total current assets | $103.36M | $113.65M | $163.31M | $169.55M | -9.1% |
| Property, plant & equipment | $66.26M | $64.68M | $65.00M | $78.97M | +2.4% |
| Goodwill & intangibles | $9.70M | $9.62M | $10.15M | $81.94M | +0.9% |
| Total assets | $190.27M | $202.74M | $270.63M | $349.13M | -6.2% |
| Total current liabilities | $21.91M | $23.31M | $31.06M | $27.91M | -6.0% |
| Total debt | $26.25M | $25.93M | $27.74M | $30.89M | +1.2% |
| Total liabilities | $46.80M | $48.75M | $58.37M | $63.56M | -4.0% |
| Retained earnings | $60.79M | $71.67M | $128.05M | $210.72M | -15.2% |
| Shareholder equity | $143.47M | $153.99M | $212.26M | $285.56M | -6.8% |
| Working capital | $81.45M | $90.35M | $132.25M | $141.63M | -9.8% |
| Net tangible assets | $133.76M | $144.37M | $202.12M | $203.63M | -7.4% |
| Shares issued | 15.38M | 15.01M | 14.85M | 14.63M | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$10.88M | -$56.38M | -$82.67M | -$14.86M | +80.7% |
| Depreciation & amortisation | $5.73M | $8.12M | $14.22M | $14.49M | -29.5% |
| Stock-based compensation | $10.08M | $13.13M | $15.24M | $14.31M | -23.2% |
| Change in working capital | -$823.00K | -$13.09M | -$12.12M | -$11.82M | +93.7% |
| Operating cash flow | $11.19M | $5.40M | -$1.79M | $4.41M | +107.1% |
| Capital expenditure | -$6.83M | -$8.33M | -$5.43M | -$7.49M | +18.1% |
| Investing cash flow | -$401.00K | -$8.33M | -$5.43M | -$7.49M | +95.2% |
| Share buybacks | -$9.48M | -$10.91M | -$5.00M | $0 | +13.1% |
| Financing cash flow | -$10.55M | -$12.73M | -$6.32M | -$4.85M | +17.1% |
| Free cash flow | $4.36M | -$2.93M | -$7.21M | -$3.08M | +248.8% |
| End cash position | $57.48M | $57.16M | $72.87M | $86.33M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $32.61M | $29.61M | $30.61M | $27.82M | $28.22M | +10.1% |
| Operating revenue | $32.61M | $29.61M | $30.61M | $27.82M | $28.22M | +10.1% |
| Cost of revenue | $11.37M | $10.62M | $11.44M | $12.23M | $13.86M | +7.1% |
| Gross profit | $21.24M | $19.00M | $19.18M | $15.58M | $14.36M | +11.8% |
| Research & development | $7.34M | $6.71M | $6.45M | $6.95M | $6.31M | +9.4% |
| Selling, general & admin | $10.95M | $17.77M | $12.08M | $11.87M | $12.23M | -38.4% |
| Total operating expense | $18.29M | $24.48M | $18.53M | $18.82M | $18.54M | -25.3% |
| Operating income | $2.95M | -$5.49M | $646.00K | -$3.23M | -$4.18M | +153.8% |
| Net interest income | $426.00K | $667.00K | $118.00K | $997.00K | $214.00K | -36.1% |
| Pre-tax income | $3.38M | -$4.82M | $764.00K | -$2.24M | -$3.97M | +170.1% |
| Tax provision | $71.00K | $235.00K | -$1.04M | $939.00K | $681.00K | -69.8% |
| Net income | $3.31M | -$5.06M | $292.00K | -$2.33M | -$3.97M | +165.4% |
| Net income to common | $3.31M | -$5.06M | $292.00K | -$2.33M | -$3.97M | +165.4% |
| Basic EPS | 0.25 | -0.37 | 0.02 | -0.16 | -0.28 | +167.6% |
| Diluted EPS | 0.24 | -0.37 | 0.02 | -0.16 | -0.28 | +164.9% |
| EBIT | $2.95M | -$5.49M | $646.00K | -$3.23M | -$4.18M | +153.8% |
| EBITDA | $4.46M | -$4.08M | $1.96M | -$1.83M | -$2.76M | +209.3% |
| Basic shares | 13.33M | 13.53M | 14.27M | 14.42M | 14.36M | -1.5% |
| Diluted shares | 13.72M | 13.53M | 14.67M | 14.42M | 14.52M | +1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.41M | $41.02M | $57.48M | $57.99M | $53.17M | -6.4% |
| Cash & short-term investments | $38.41M | $41.02M | $57.48M | $57.99M | $53.17M | -6.4% |
| Accounts receivable | $29.06M | $25.77M | $23.69M | $22.19M | $23.95M | +12.8% |
| Inventory | $28.57M | $22.84M | $18.79M | $16.28M | $16.92M | +25.1% |
| Total current assets | $99.19M | $93.56M | $103.36M | $101.59M | $99.32M | +6.0% |
| Property, plant & equipment | $65.05M | $65.15M | $66.26M | $64.91M | $65.81M | -0.2% |
| Goodwill & intangibles | $9.47M | $9.54M | $9.70M | $9.70M | $9.72M | -0.7% |
| Total assets | $183.47M | $179.39M | $190.27M | $189.44M | $187.68M | +2.3% |
| Total current liabilities | $22.15M | $20.97M | $21.91M | $19.09M | $16.08M | +5.6% |
| Total debt | $25.25M | $25.74M | $26.25M | $24.51M | $24.99M | -1.9% |
| Total liabilities | $46.19M | $45.49M | $46.80M | $42.63M | $40.01M | +1.6% |
| Retained earnings | $59.04M | $55.73M | $60.79M | $60.49M | $62.82M | +5.9% |
| Shareholder equity | $137.28M | $133.90M | $143.47M | $146.81M | $147.67M | +2.5% |
| Working capital | $77.04M | $72.59M | $81.45M | $82.50M | $83.24M | +6.1% |
| Net tangible assets | $127.81M | $124.36M | $133.76M | $137.10M | $137.96M | +2.8% |
| Shares issued | 13.31M | 15.63M | 15.38M | 15.36M | 15.35M | -14.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $3.31M | -$5.06M | $292.00K | -$2.33M | -$3.97M | +165.4% |
| Depreciation & amortisation | $1.50M | $1.41M | $1.32M | $1.40M | $1.42M | +7.0% |
| Stock-based compensation | $1.83M | $6.64M | $2.46M | $2.21M | $2.55M | -72.4% |
| Change in working capital | -$9.19M | -$9.19M | -$1.13M | $4.41M | -$3.83M | -0.0% |
| Operating cash flow | -$684.00K | -$4.85M | $4.64M | $6.87M | -$189.00K | +85.9% |
| Capital expenditure | -$1.45M | -$1.43M | -$648.00K | -$1.89M | -$1.47M | -1.3% |
| Investing cash flow | -$1.28M | -$1.24M | $198.00K | -$1.73M | -$539.00K | -3.3% |
| Share buybacks | -$853.00K | -$8.69M | -$5.51M | $0 | $0 | +90.2% |
| Financing cash flow | -$701.00K | -$10.35M | -$5.28M | -$13.00K | $179.00K | +93.2% |
| Free cash flow | -$2.13M | -$6.28M | $3.99M | $4.98M | -$1.66M | +66.0% |
| End cash position | $38.41M | $41.02M | $57.48M | $57.99M | $53.17M | -6.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
20.00
+4.6% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
0
Contracts, this expiry
Put volume
13
Contracts, this expiry
Heaviest call OI
22.50
0 contracts
Heaviest put OI
20.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.03 | 0.42 | +1,300.0% |
| Mar 2026 | 0.00 | 0.27 | 0.0% |
| Dec 2025 | 0.02 | 0.31 | +1,450.0% |
| Sep 2025 | 0.02 | 0.04 | +100.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.42 | 1 | $29.44M | +5.8% |
| Next quarter | 0.19 | 1 | $29.99M | -2.0% |
| Current year | 1.05 | 1 | $121.64M | +7.8% |
| Next year | 0.95 | 1 | $128.26M | +5.4% |
Analyst targets & ownership
Mean target$23.00
High target$23.00
Low target$23.00
Implied upside20.29%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders6.40%
Held by institutions93.64%
Institutions holding189
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
19.86
-3.72% from price
SMA 20
20.38
-6.20% from price
SMA 50
20.48
-6.66% from price
SMA 100
17.74
+7.79% from price
SMA 200
15.08
+26.81% from price
EMA 12
19.89
-3.88% from price
EMA 26
20.18
-5.27% from price
EMA 50
19.72
-3.04% from price
RSI (14)
38.5
Neutral
MACD (12,26,9)
-0.29
Hist -0.21
ATR (14)
0.67
3.51% of price
Realised vol 30D
27.2%
Annualised
Bollinger upper
21.69
20, 2σ
Bollinger lower
19.08
20, 2σ
50 / 200 cross
Golden
20.48 vs 15.08
Trend bias
Above 200
+26.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.62
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
27.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.6%
Peak to trough
Max drawdown 5Y
-82.0%
Peak to trough
ATR 14
0.67
3.51% of price
Beta (reported)
0.21
5Y monthly, from filing
Short interest
Shares short
381.38K
Prior 337.21K
Change vs prior
+13.1%
Shorts adding
% of float
3.74%
Normal
% of shares out
2.85%
Against total outstanding
Days to cover
3.7
Liquid
Float
11.29M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 30, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Feb 27, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Jan 9, 26 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Nov 6, 25 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Sep 23, 25 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Jul 31, 25 | Barrington Research | MAINTAINED | Outperform | Outperform |
| May 12, 25 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Mar 13, 25 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Nov 1, 24 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Oct 22, 24 | Barrington Research | MAINTAINED | Outperform | Outperform |
| Aug 9, 24 | Barrington Research | MAINTAINED | Outperform | Outperform |
| May 29, 24 | Stephens & Co. | MAINTAINED | Equal-Weight | Equal-Weight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-8 · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-14
Corporate Changes & Voting Matters
8-K · 2026-06-23
Proxy Statements
DEFA14A · 2026-06-08
Proxy Statements
DEFA14A · 2026-06-01
Periodic Financial Reports
10-Q · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-29
Annual Report to Shareholders
ARS · 2026-04-28
Headlines
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Zacks · 12d ago
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Zacks · 12d ago
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Zacks · 14d ago
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
Zacks · 16d ago
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Zacks · 19d ago
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Zacks · 21d ago
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
Zacks · 22d ago
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Zacks · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.